title: Plasma exchange for renal disease: evidence and use 2011.
abstract: Over the past 37 year the role of plasma exchange in the treatment of patients with renal disease has undergone several changes. The majority of the changes for the use of plasma exchange relied on randomized control trials and delineations of mechanisms that potentially would benefit from the use of plasma exchange. Over the past 11 years plasma exchange indications for renal disease, the absolute numbers have been relatively unchanged but the indications are quite different. The Canadian Apheresis Group indicated in 2010 that TTP/HUS is still the number 1 indication at 63% of the total plasma exchange activity for renal disease but P and C ANCA Vasculitis had risen to 14% followed by renal transplant at 10%, Goodpasture's Syndrome at 6% and transplant FSGS at 5% with Cryoglobulinemia 2% and Myeloma Nephropathy had dropped dramatically to less than 1% with no cases of SLE reported. This report describes the most common indications for plasma exchange in patient's with renal disease and the evidence that supports it's use in 2011.
authors.affiliation: London Health Science Centre, Western University Canada. William.Clark@LHSC.ON.CA
authors.forename: W F
authors.initials: WF
authors.lastname: Clark
mesh_terms: D019867:Anti-Glomerular Basement Membrane Disease / Q000628:therapy; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000628:therapy; D002170:Canada; D003449:Cryoglobulinemia / Q000628:therapy; D005923:Glomerulosclerosis, Focal Segmental / Q000628:therapy; D006463:Hemolytic-Uremic Syndrome / Q000628:therapy; D006801:Humans; D007674:Kidney Diseases / Q000628:therapy*; D016030:Kidney Transplantation; D010951:Plasma Exchange / Q000706:statistics & numerical data / Q000639:trends; D010956:Plasmapheresis; D011697:Purpura, Thrombotic Thrombocytopenic / Q000628:therapy